Wells Fargo & Company Syndax Pharmaceuticals Inc Transaction History

Wells Fargo & Company

$407 Billion
Q2 2024

A detailed history of Wells Fargo & Company transactions in Syndax Pharmaceuticals Inc stock. As of the latest transaction made, Wells Fargo & Company holds 31,169 shares of SNDX stock, worth $595,327. This represents 0.0% of its overall portfolio holdings.

Number of Shares

31,169

Previous 29,173 6.84%

Holding current value

$595,327

Previous $694,000 7.93%

% of portfolio

0.0%

Previous 0.0%

17 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	BUY	$18.82 - $23.79 $37,564 - $47,484	1,996 Added 6.84%	31,169 $639,000
Q1 2024 May 10, 2024	BUY	$19.71 - $24.57 $123,778 - $154,299	6,280 Added 27.43%	29,173 $694,000
Q4 2023 Feb 09, 2024	SELL	$11.39 - $21.67 $532,790 - $1.01 Million	-46,777 Reduced 67.14%	22,893 $494,000
Q3 2023 Nov 13, 2023	SELL	$14.52 - $21.77 $279,176 - $418,571	-19,227 Reduced 21.63%	69,670 $1.01 Million
Q2 2023 Aug 15, 2023	BUY	$19.35 - $22.31 $502,577 - $579,457	25,973 Added 41.28%	88,897 $1.86 Million
Q1 2023 May 12, 2023	BUY	$20.66 - $28.98 $1.2 Million - $1.68 Million	57,849 Added 1139.88%	62,924 $1.33 Million
Q4 2022 Feb 13, 2023	SELL	$20.64 - $26.24 $41,218 - $52,401	-1,997 Reduced 28.24%	5,075 $129,000
Q3 2022 Nov 14, 2022	BUY	$18.51 - $24.79 $12,531 - $16,782	677 Added 10.59%	7,072 $170,000
Q2 2022 Aug 12, 2022	SELL	$13.64 - $19.48 $68,186 - $97,380	-4,999 Reduced 43.87%	6,395 $122,000
Q1 2022 May 16, 2022	SELL	$14.84 - $22.15 $219,157 - $327,111	-14,768 Reduced 56.45%	11,394 $198,000
Q4 2021 Feb 14, 2022	BUY	$15.23 - $22.47 $315,428 - $465,376	20,711 Added 379.95%	26,162 $572,000
Q2 2021 Aug 16, 2021	SELL	$13.42 - $25.18 $59,101 - $110,892	-4,404 Reduced 44.69%	5,451 $94,000
Q1 2021 May 13, 2021	SELL	$19.28 - $24.59 $1.01 Million - $1.28 Million	-52,250 Reduced 84.13%	9,855 $219,000
Q4 2020 Feb 09, 2021	SELL	$15.1 - $26.44 $10,117 - $17,714	-670 Reduced 1.07%	62,105 $1.38 Million
Q3 2020 Nov 05, 2020	SELL	$13.39 - $17.48 $328,188 - $428,434	-24,510 Reduced 28.08%	62,775 $926,000
Q2 2020 Aug 13, 2020	BUY	$8.94 - $20.98 $560,180 - $1.31 Million	62,660 Added 254.46%	87,285 $1.29 Million
Q1 2020 May 14, 2020	BUY	$6.65 - $12.03 $163,756 - $296,238	24,625 New	24,625 $270,000

Others Institutions Holding SNDX

# of Institutions

202

Shares Held

87.1M

Call Options Held

268K

Put Options Held

76.8K

View Full List

About Syndax Pharmaceuticals Inc

Ticker SNDX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 56,565,200
Market Cap $1.08B
Description
Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are SNDX-5613, which is in phase 1/2 clinical trial targeting the binding interaction of Menin with the mixed lineage leukemia 1 protein for the treatment of MLL-rearranged (MLLr) and nucleophosmin...

More about SNDX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

News

Stay updated on Wells Fargo & Company with notifications on news.

Account

Wells Fargo & Company Syndax Pharmaceuticals Inc Transaction History